Completed NA INTERVENTIONAL 2-arm NCT04889950

Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction

A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel Versus Lipiflow in the Treatment of Meibomian Gland Dysfunction.

Sponsor: Novoxel Ltd.

Conditions Dry Eye Dry Eye Syndromes Meibomian Gland Dysfunction

Interventions LipiFlow Tixel C

Updated 8 times since 2021 Last updated: Nov 14, 2024 Started: Oct 26, 2021 Primary completion: Jan 4, 2023 Completion: Feb 8, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Dry Eye and Dry Eye Syndromes, this trial is completed. The trial is conducted by Novoxel Ltd. and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Dec 2024 — Present [monthly]

Completed NA
Sep 2024 — Dec 2024 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Mar 2023 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
May 2022 — Mar 2023 [monthly]

Recruiting NA

▶ Show 3 earlier versions

Jan 2022 — May 2022 [monthly]

Recruiting NA
Dec 2021 — Jan 2022 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jun 2021 — Dec 2021 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novoxel Ltd.

Data source: Novoxel Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel